BridgeBio Pharma (BBIO) EBITDA (2018 - 2026)

BridgeBio Pharma has reported EBITDA for 9 years, with the latest figure at -$106.0 million in Q1 2026.

• Quarterly EBITDA fell 1.52% year-over-year to -$106.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$525.0 million (up 24.75% YoY) and the FY2025 annual result came in at -$523.4 million, up 11.73% from the prior year.
• EBITDA improved to -$106.0 million in Q1 2026 per BBIO's latest filing, from -$139.6 million in the prior quarter.
• Over five years, EBITDA peaked at $343000.0 in Q1 2024 and troughed at -$226.0 million in Q4 2024.
• A 5-year average of -$137.8 million and a median of -$139.6 million in 2025 frame the typical range for EBITDA.
• The sharpest annual moves came in 2024 and 2025: EBITDA jumped 100.27% in 2024, then plunged 30529.15% in 2025.
• Over 5 years, EBITDA stood at -$129.2 million in 2022, then plunged by 37.28% to -$177.4 million in 2023, then retreated by 27.4% to -$226.0 million in 2024, then jumped by 38.25% to -$139.6 million in 2025, then advanced by 24.08% to -$106.0 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$106.0 million, -$139.6 million, and -$145.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.